Choose License Type
Dengue fever is an acute febrile disease transmitted by female Aedes mosquito infected with any one of the four dengue viruses. Dengue fever, along with Dengue Shock Syndrome (DSS) and Dengue Hemorrhagic Fever (DHF) has emerged as a great public health concern. Dengue fever is common in the tropics, with risk levels varying depending on rainfall, temperature, relative humidity, and unplanned rapid urbanization. The spike in the number of dengue cases has led to increase the demand for dengue testing across the globe.
The aim of the report is to estimate the market size for dengue testing and the future growth potential of the market for dengue testing across various segments, such as product, and end-users.
The market has been studied for historic years from 2018 and 2019, with the base year of estimation as 2019 and forecast from 2020 to 2028. Factors such as growing incidences of dengue fever worldwide, rapid urbanization and climate change leading to increased prevalence along with increase in awareness campaigns for dengue are the key drivers of the dengue testing market.
By product, ELISA-based tests held substantial share of the global dengue testing market owing to its high sensitivity and specificity. An enzyme-linked immunosorbent assay (ELISA), which tests anti-DENV IgM or IgG antibodies in patient serum, is the most commonly used method for diagnosing dengue fever. Early diagnosis and management of the disease helps to minimize morbidity and mortality rates associated with serious types of the disease, as well as the possibility of larger outbreaks.
Asia Pacific dominated the global dengue testing market in 2019. The dominant share is attributable to large number of dengue infected patients in the Southeast Asian countries. For instance, around 131,000 cases of dengue were reported in Malaysia, Philippines reported 420,000 cases and Vietnam reported 320,000 cases. The robust spread of the dengue across Southeast Asia has fuelled the demand for diagnostic tests for the disease.
Major industry players are making heavy investments in research projects, which is expected to ensure market growth during the forecast period. Industry players are focused on developing novel diagnostic test kits which in the coming years will further increase the overall growth of the market
Key Segments of the Global Dengue Testing Market
Product Overview, 2018-2028 (USD Million)
End-user Overview, 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
Important Companies in Global Dengue Testing Market
Reasons for the study
What does the report include?
Who should buy this report?
Dengue fever is an acute febrile disease transmitted by female Aedes mosquito infected with any one of the four dengue viruses. Dengue fever, along with Dengue Shock Syndrome (DSS) and Dengue Hemorrhagic Fever (DHF) has emerged as a great public health concern. Dengue fever is common in the tropics, with risk levels varying depending on rainfall, temperature, relative humidity, and unplanned rapid urbanization. The spike in the number of dengue cases has led to increase the demand for dengue testing across the globe.
The aim of the report is to estimate the market size for dengue testing and the future growth potential of the market for dengue testing across various segments, such as product, and end-users.
The market has been studied for historic years from 2018 and 2019, with the base year of estimation as 2019 and forecast from 2020 to 2028. Factors such as growing incidences of dengue fever worldwide, rapid urbanization and climate change leading to increased prevalence along with increase in awareness campaigns for dengue are the key drivers of the dengue testing market.
By product, ELISA-based tests held substantial share of the global dengue testing market owing to its high sensitivity and specificity. An enzyme-linked immunosorbent assay (ELISA), which tests anti-DENV IgM or IgG antibodies in patient serum, is the most commonly used method for diagnosing dengue fever. Early diagnosis and management of the disease helps to minimize morbidity and mortality rates associated with serious types of the disease, as well as the possibility of larger outbreaks.
Asia Pacific dominated the global dengue testing market in 2019. The dominant share is attributable to large number of dengue infected patients in the Southeast Asian countries. For instance, around 131,000 cases of dengue were reported in Malaysia, Philippines reported 420,000 cases and Vietnam reported 320,000 cases. The robust spread of the dengue across Southeast Asia has fuelled the demand for diagnostic tests for the disease.
Major industry players are making heavy investments in research projects, which is expected to ensure market growth during the forecast period. Industry players are focused on developing novel diagnostic test kits which in the coming years will further increase the overall growth of the market
Key Segments of the Global Dengue Testing Market
Product Overview, 2018-2028 (USD Million)
End-user Overview, 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
Important Companies in Global Dengue Testing Market
Reasons for the study
What does the report include?
Who should buy this report?
1. Introduction
1.1. Introduction
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.3. Market Size Estimation
2.4. Market Forecast
2.5. Data Triangulation
2.6. Assumptions and Limitations
3. Market Outlook
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. Porter’s Five Forces Analysis
3.4. Regulatory Landscape
3.5. COVID-19 Impact Analysis
4. Dengue Testing Market by Product, 2018-2028 (USD Million)
4.1. ELISA-based Tests
4.2. RT-PCR based Tests
4.3. Dengue IgG/IgM Rapid Tests
5. Dengue Testing Market by End-user, 2018-2028 (USD Million)
5.1. Hospitals
5.2. Diagnostic Centers & Clinics
5.3. Others
6. Dengue Testing Market by Region, 2018-2028 (USD Million)
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. France
6.2.4. Spain
6.2.5. Italy
6.2.6. Rest of Europe
6.3. Asia Pacific
6.3.1. China
6.3.2. Japan
6.3.3. India
6.3.4. Rest of APAC
6.4. Latin America
6.4.1. Brazil
6.4.2. Mexico
6.4.3. Rest of Latin America
6.5. Middle East & Africa
6.5.1. GCC
6.5.2. South Africa
6.5.3. Rest of Middle East & Africa
7. Competitive Landscape
7.1. Company Ranking/Market Share Analysis
7.2. Strategic Initiatives
7.2.1. Mergers & Acquisitions
7.2.2. New Product Launch
7.2.3. Investments
7.2.4. Expansion
7.2.5. Others
8. Company Profiles
8.1. Thermo Fisher Scientific
8.1.1. Overview
8.1.2. Products Portfolio
8.1.3. Recent Initiatives
8.1.4. Company Financials
8.2. F. Hoffmann La Roche Ltd.
8.3. Euroimmmun AG (Perkin Elmer, Inc.)
8.4. Abbott Laboratories
8.5. InBios International, Inc.
8.6. NovaTec Immunodiagostica GmbH
8.7. DiaSorin
8.8. Certest Biotec S.L.
8.9. OriGene Technologies
8.10. Abnova Corporation
8.11. Other Prominent Players